Search clinical trials for: Immunological adjuvant

Total 23977 results

AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China
Amgen

Recruiting

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Melanoma

Italy, Spain, South Africa, Japan, Serbia, Bosnia and Herzegovina, United States, Argentina, Chile, Georgia, Malaysia, Korea, Republic of, France, Germany, Croatia, Thailand, Brazil, Taiwan, Romania, Mexico, Netherlands
National Cancer Institute (NCI)

Recruiting

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Neoplasms | Esophageal Neoplasms | Esophagus Cancer | Esophagus Neoplasm | Neoplasms, Esophageal | Esophageal Cancer (EsC)

United States
Erasmus Medical Center

Recruiting

TEIPP Immunotherapy in Patients With NSCLC (TEIPP)

Non Small Cell Lung Cancer

Netherlands
Peking University
Merck Sharp & Dohme LLC; Cancer Institute and Hospital, Chinese Academy of... and other collaborators

Recruiting

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Stage IIIA Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer | Stage IIIB(N2) Non-small Cell Lung Cancer

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Short-course Trastuzumab, Pertuzumab With Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

Breast Cancer

China
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; InSightec

Not yet recruiting

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Recurrent Glioblastoma

United States
Fudan University

Not yet recruiting

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Breast Cancer
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

Colorectal Cancer | Chemotherapy Effect

China
Leiden University Medical Center
University Medical Center Groningen; Erasmus Medical Center

Not yet recruiting

Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study (Apollo)

Squamous Cell Cancer | Vulva Cancer | Vulva Neoplasm
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab

HER2-positive Breast Cancer | Early-stage Breast Cancer | Adjuvant Treatment After Trastuzumab | RCB Classification 1-2 | Neratini

China
Spanish Breast Cancer Research Group
AstraZeneca

Recruiting

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, France, Netherlands, Italy, Canada, Sweden
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Head and Neck Squamous Cell Carcinomas

China
Fourth Affiliated Hospital of Guangxi Medical University
Guilin Medical University, China; Wuzhou Red Cross Hospital; Second Affiliated... and other collaborators

Recruiting

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma by AJCC V8 Stage

China
Mayo Clinic

Not yet recruiting

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Lung

United States
Biogen

Recruiting

A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Multiple Sclerosis

United States
Fundación GECP

Recruiting

DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors (DUMAS)

NSCLC | Pancoast Tumor

Spain
M.D. Anderson Cancer Center
Genentech, Inc.

Recruiting

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

United States
Shanghai Pudong Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study (easy laugh)

Breast Cancer

China
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
Regeneron Pharmaceuticals

Recruiting

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Melanoma

United States, Australia, Spain, United Kingdom, Canada, Brazil, Mexico, Germany, Ireland, South Africa, France, Israel, Georgia, Turkey, Italy, Poland, Chile, Argentina, Belgium, Czechia, Romania, Greece
CanariaBio Inc.
Raptim Research Pvt. Ltd

Recruiting

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Fallopian Tube Neoplasms | Ovarian Cancer | Peritoneal Carcinoma | Ovarian Serous Adenocarcinoma | Ovarian Neoplasm Epithelial

India
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shenzhen Sixth People's Hospital; Zhongshan People's Hospital, Guangdong, China

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Head and Neck Squamous Cell Carcinomas

China
Duke University
Regeneron Pharmaceuticals

Recruiting

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Non-small Cell Lung Cancer (NSCLC)

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Not yet recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)

Mucosal Melanoma

Australia
Wan-Guang Zhang
BeiGene; Geneplus-Beijing Co. Ltd.; Simcere Pharmaceutical Co., Ltd; Chinese Cooperative... and other collaborators

Recruiting

Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC (CCGLC-007)

Hepatocellular Carcinoma

China
National Cancer Centre, Singapore
National University Hospital, Singapore; Singapore General Hospital; Tan Tock... and other collaborators

Recruiting

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (EMPHASIS)

Hepatocellular Carcinoma

Singapore
Okayama University
Merck Sharp & Dohme LLC

Recruiting

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | BRCA1 Mutation | BRCA2 Mutation | BRCA Mutation | BRCA-Associated Breast Carcinoma

Japan
Brown University
AstraZeneca

Recruiting

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Esophageal Cancer | Esophageal Adenocarcinoma | HER-2 Protein Overexpression | Gastroesophageal-junction Cancer

United States
University Health Network, Toronto
Clinica Universidad de Navarra, Universidad de Navarra; University of Milan

Recruiting

Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA))

Hepatocellular Carcinoma

Spain, Canada, Italy
Peking Union Medical College Hospital

Recruiting

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

Rectal Cancer | Colon Cancer | Chemotherapy Effect | PTC | Exon Mutation

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study for the Adjuvant Treatment of Breast Cancer

Breast Cancer

China
Institut de cancérologie Strasbourg Europe

Not yet recruiting

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C) (PHARE-C)

HER2-positive Breast Cancer
Ospedale Policlinico San Martino
Bayer; Associazione Italiana per la Ricerca sul Cancro; Gruppo Italiano per lo...

Recruiting

Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial (VIVA)

Colorectal Cancer Stage IV | No Evidence of Disease State

Italy
Anhui Provincial Hospital

Recruiting

Neoadjuvant Chemoradiotherapy Combined With Camrelizumab and Nimotuzumab for Esophageal Squamous Cell Carcinoma

Toxicity, Drug

China
Sun Yat-sen University
The First Hospital of Nanchang

Not yet recruiting

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
University of Texas Southwestern Medical Center

Recruiting

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

Renal Cell Carcinoma

United States
Fujian Medical University Union Hospital

Recruiting

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Breast Cancer | Adjuvant Therapy

China
University of Virginia

Recruiting

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer (Breast53)

Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III

United States
IO Biotech
Merck Sharp & Dohme LLC; Theradex; Almac

Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Melanoma | Squamous Cell Carcinoma of Head and Neck

United States, Australia, Denmark, Spain, France, Germany
Guangdong Provincial People's Hospital

Recruiting

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma

China
Leiden University Medical Center
Canadian Institutes of Health Research (CIHR); AstraZeneca; National Cancer Institute... and other collaborators

Recruiting

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO)

Endometrial Cancer

Netherlands, Canada, France, United Kingdom
Shanghai Zhongshan Hospital
Bristol-Myers Squibb

Recruiting

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Esophageal Squamous Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

HER2-positive Breast Cancer | Adjuvant Therapy

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFR

China
AstraZeneca
Parexel

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)

Non-small Cell Lung Cancer

Hungary, United States, Italy, Belgium, Spain, France, Korea, Republic of, Taiwan, Turkey, Ireland, Portugal, Canada
M.D. Anderson Cancer Center

Recruiting

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

Thyroid

United States

Search clinical trials for: Immunological adjuvant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations